LONDON - Shire plc is now poised to challenge the blockbuster status of Genzyme's Cerezyme, after reporting positive Phase III data and receiving approval of the treatment protocol, enabling it to start the rolling application of its enzyme replacement for Gaucher's disease under the FDA's fast-track process. (BioWorld International) Read More
